NL194940C - Virusstam en vaccin ter voorkoming van varkensreproductie- en -respiratiesyndroom. - Google Patents

Virusstam en vaccin ter voorkoming van varkensreproductie- en -respiratiesyndroom. Download PDF

Info

Publication number: NL194940C
Authority: NL; Netherlands
Prior art keywords: virus; vaccine; prrs; sows; pig
Prior art date: 1993-09-17

Application number

NL9401414A

Other languages

English (en)

Dutch (nl)

Other versions

NL9401414A (nl

NL194940B (nl

Inventor

Juan Plana Duran

Original Assignee

Iberica Cyanamid

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-17

Filing date

1994-08-31

Publication date

2003-08-04

1994-08-31 Application filed by Iberica Cyanamid filed Critical Iberica Cyanamid

1995-04-18 Publication of NL9401414A publication Critical patent/NL9401414A/nl

2003-04-01 Publication of NL194940B publication Critical patent/NL194940B/nl

2003-08-04 Application granted granted Critical

2003-08-04 Publication of NL194940C publication Critical patent/NL194940C/nl

Links

241000700605 Viruses Species 0.000 title claims description 134
229960005486 vaccine Drugs 0.000 title claims description 92
208000011580 syndromic disease Diseases 0.000 title claims description 10
230000029058 respiratory gaseous exchange Effects 0.000 title description 5
241000282898 Sus scrofa Species 0.000 claims description 56
208000015181 infectious disease Diseases 0.000 claims description 51
210000004072 lung Anatomy 0.000 claims description 43
210000004027 cell Anatomy 0.000 claims description 32
239000002671 adjuvant Substances 0.000 claims description 29
208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 claims description 22
108700026244 Open Reading Frames Proteins 0.000 claims description 19
210000001132 alveolar macrophage Anatomy 0.000 claims description 19
230000003612 virological effect Effects 0.000 claims description 19
238000000034 method Methods 0.000 claims description 14
239000000427 antigen Substances 0.000 claims description 13
102000036639 antigens Human genes 0.000 claims description 13
108091007433 antigens Proteins 0.000 claims description 13
210000002540 macrophage Anatomy 0.000 claims description 13
230000000241 respiratory effect Effects 0.000 claims description 10
239000000203 mixture Substances 0.000 claims description 9
239000000126 substance Substances 0.000 claims description 9
206010069767 H1N1 influenza Diseases 0.000 claims description 8
208000009620 Orthomyxoviridae Infections Diseases 0.000 claims description 8
230000036755 cellular response Effects 0.000 claims description 8
244000052769 pathogen Species 0.000 claims description 8
201000010740 swine influenza Diseases 0.000 claims description 8
208000005577 Gastroenteritis Diseases 0.000 claims description 7
230000000890 antigenic effect Effects 0.000 claims description 6
239000003755 preservative agent Substances 0.000 claims description 6
238000003501 co-culture Methods 0.000 claims description 5
230000002779 inactivation Effects 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
239000000839 emulsion Substances 0.000 claims description 4
229940031348 multivalent vaccine Drugs 0.000 claims description 4
230000002335 preservative effect Effects 0.000 claims description 4
230000000694 effects Effects 0.000 claims description 3
230000001900 immune effect Effects 0.000 claims description 3
241000606748 Actinobacillus pleuropneumoniae Species 0.000 claims description 2
241000588724 Escherichia coli Species 0.000 claims description 2
241000606807 Glaesserella parasuis Species 0.000 claims description 2
108010065805 Interleukin-12 Proteins 0.000 claims description 2
108090000978 Interleukin-4 Proteins 0.000 claims description 2
241000589902 Leptospira Species 0.000 claims description 2
241000702670 Rotavirus Species 0.000 claims description 2
238000004113 cell culture Methods 0.000 claims description 2
231100000676 disease causative agent Toxicity 0.000 claims description 2
239000002502 liposome Substances 0.000 claims description 2
102000006240 membrane receptors Human genes 0.000 claims description 2
108020004084 membrane receptors Proteins 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
230000017074 necrotic cell death Effects 0.000 claims description 2
108091028043 Nucleic acid sequence Proteins 0.000 claims 2
210000004754 hybrid cell Anatomy 0.000 claims 2
241000588779 Bordetella bronchiseptica Species 0.000 claims 1
241000186810 Erysipelothrix rhusiopathiae Species 0.000 claims 1
241000480044 IAS virus Species 0.000 claims 1
108010002352 Interleukin-1 Proteins 0.000 claims 1
108010002350 Interleukin-2 Proteins 0.000 claims 1
108090001005 Interleukin-6 Proteins 0.000 claims 1
241000606856 Pasteurella multocida Species 0.000 claims 1
241000711493 Porcine respiratory coronavirus Species 0.000 claims 1
229940031416 bivalent vaccine Drugs 0.000 claims 1
238000012258 culturing Methods 0.000 claims 1
230000002708 enhancing effect Effects 0.000 claims 1
229940051027 pasteurella multocida Drugs 0.000 claims 1
241000061450 x Ascocenda Species 0.000 claims 1
241001465754 Metazoa Species 0.000 description 38
201000010099 disease Diseases 0.000 description 30
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
241000710788 Lelystad virus Species 0.000 description 26
150000001413 amino acids Chemical class 0.000 description 26
238000012360 testing method Methods 0.000 description 25
239000000047 product Substances 0.000 description 16
238000002255 vaccination Methods 0.000 description 16
210000004369 blood Anatomy 0.000 description 13
239000008280 blood Substances 0.000 description 13
239000012071 phase Substances 0.000 description 13
230000035935 pregnancy Effects 0.000 description 13
108090000623 proteins and genes Proteins 0.000 description 13
108020004705 Codon Proteins 0.000 description 12
239000002773 nucleotide Substances 0.000 description 12
125000003729 nucleotide group Chemical group 0.000 description 12
102000004169 proteins and genes Human genes 0.000 description 11
230000000405 serological effect Effects 0.000 description 11
208000029523 Interstitial Lung disease Diseases 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
238000011081 inoculation Methods 0.000 description 10
238000002955 isolation Methods 0.000 description 10
230000004044 response Effects 0.000 description 10
239000002299 complementary DNA Substances 0.000 description 9
238000004519 manufacturing process Methods 0.000 description 9
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 8
238000012512 characterization method Methods 0.000 description 8
230000000875 corresponding effect Effects 0.000 description 8
230000001850 reproductive effect Effects 0.000 description 8
239000000725 suspension Substances 0.000 description 8
101000787132 Acidithiobacillus ferridurans Uncharacterized 8.2 kDa protein in mobL 3'region Proteins 0.000 description 7
101000827262 Acidithiobacillus ferrooxidans Uncharacterized 18.9 kDa protein in mobE 3'region Proteins 0.000 description 7
101000811747 Antithamnion sp. UPF0051 protein in atpA 3'region Proteins 0.000 description 7
101000827607 Bacillus phage SPP1 Uncharacterized 8.5 kDa protein in GP2-GP6 intergenic region Proteins 0.000 description 7
101000961975 Bacillus thuringiensis Uncharacterized 13.4 kDa protein Proteins 0.000 description 7
101000964407 Caldicellulosiruptor saccharolyticus Uncharacterized 10.7 kDa protein in xynB 3'region Proteins 0.000 description 7
101000768777 Haloferax lucentense (strain DSM 14919 / JCM 9276 / NCIMB 13854 / Aa 2.2) Uncharacterized 50.6 kDa protein in the 5'region of gyrA and gyrB Proteins 0.000 description 7
101710126256 Hydrolase in agr operon Proteins 0.000 description 7
101000607404 Infectious laryngotracheitis virus (strain Thorne V882) Protein UL24 homolog Proteins 0.000 description 7
101000735632 Klebsiella pneumoniae Uncharacterized 8.8 kDa protein in aacA4 3'region Proteins 0.000 description 7
101000818100 Spirochaeta aurantia Uncharacterized 12.7 kDa protein in trpE 5'region Proteins 0.000 description 7
101001037658 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) Glucokinase Proteins 0.000 description 7
230000036528 appetite Effects 0.000 description 7
235000019789 appetite Nutrition 0.000 description 7
238000000746 purification Methods 0.000 description 7
238000012163 sequencing technique Methods 0.000 description 7
239000000243 solution Substances 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
101000787133 Acidithiobacillus ferridurans Uncharacterized 12.3 kDa protein in mobL 3'region Proteins 0.000 description 6
101000827603 Bacillus phage SPP1 Uncharacterized 10.2 kDa protein in GP2-GP6 intergenic region Proteins 0.000 description 6
208000001726 Classical Swine Fever Diseases 0.000 description 6
206010020843 Hyperthermia Diseases 0.000 description 6
101000977786 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized 9.7 kDa protein in PE 3'region Proteins 0.000 description 6
241000255969 Pieris brassicae Species 0.000 description 6
101001113905 Rice tungro bacilliform virus (isolate Philippines) Protein P4 Proteins 0.000 description 6
125000003275 alpha amino acid group Chemical group 0.000 description 6
230000036031 hyperthermia Effects 0.000 description 6
230000003902 lesion Effects 0.000 description 6
208000009305 pseudorabies Diseases 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
230000000087 stabilizing effect Effects 0.000 description 6
101000765604 Bacillus subtilis (strain 168) FlaA locus 22.9 kDa protein Proteins 0.000 description 5
101000964402 Caldicellulosiruptor saccharolyticus Uncharacterized protein in xynC 3'region Proteins 0.000 description 5
206010024769 Local reaction Diseases 0.000 description 5
101000977779 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized 33.9 kDa protein in PE 3'region Proteins 0.000 description 5
101000827630 Narcissus mosaic virus Uncharacterized 10 kDa protein Proteins 0.000 description 5
125000000539 amino acid group Chemical group 0.000 description 5
230000007969 cellular immunity Effects 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
210000003754 fetus Anatomy 0.000 description 5
230000001717 pathogenic effect Effects 0.000 description 5
230000007918 pathogenicity Effects 0.000 description 5
101000977065 Acidithiobacillus ferridurans Uncharacterized 11.6 kDa protein in mobS 3'region Proteins 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
101000861180 Cupriavidus necator (strain ATCC 17699 / DSM 428 / KCTC 22496 / NCIMB 10442 / H16 / Stanier 337) Uncharacterized protein H16_B0147 Proteins 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
208000007212 Foot-and-Mouth Disease Diseases 0.000 description 4
241000710198 Foot-and-mouth disease virus Species 0.000 description 4
108020000999 Viral RNA Proteins 0.000 description 4
206010000210 abortion Diseases 0.000 description 4
238000009395 breeding Methods 0.000 description 4
230000001488 breeding effect Effects 0.000 description 4
239000012894 fetal calf serum Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
244000144980 herd Species 0.000 description 4
206010061218 Inflammation Diseases 0.000 description 3
241000125945 Protoparvovirus Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
241000282887 Suidae Species 0.000 description 3
231100000176 abortion Toxicity 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
239000008346 aqueous phase Substances 0.000 description 3
VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 3
238000010804 cDNA synthesis Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000010367 cloning Methods 0.000 description 3
238000007596 consolidation process Methods 0.000 description 3
230000037029 cross reaction Effects 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
238000003119 immunoblot Methods 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
239000002609 medium Substances 0.000 description 3
230000032696 parturition Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
229960000380 propiolactone Drugs 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical group [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
238000005406 washing Methods 0.000 description 3
FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
241000233866 Fungi Species 0.000 description 2
BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 2
238000011887 Necropsy Methods 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
102000003992 Peroxidases Human genes 0.000 description 2
108091034057 RNA (poly(A)) Proteins 0.000 description 2
108091027544 Subgenomic mRNA Proteins 0.000 description 2
108020005038 Terminator Codon Proteins 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
230000004596 appetite loss Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
238000012790 confirmation Methods 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
210000005069 ears Anatomy 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
238000010828 elution Methods 0.000 description 2
230000012173 estrus Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
230000037406 food intake Effects 0.000 description 2
235000012631 food intake Nutrition 0.000 description 2
230000004927 fusion Effects 0.000 description 2
239000000499 gel Substances 0.000 description 2
230000036449 good health Effects 0.000 description 2
230000035931 haemagglutination Effects 0.000 description 2
230000036541 health Effects 0.000 description 2
229940031551 inactivated vaccine Drugs 0.000 description 2
239000012678 infectious agent Substances 0.000 description 2
230000006651 lactation Effects 0.000 description 2
208000019017 loss of appetite Diseases 0.000 description 2
235000021266 loss of appetite Nutrition 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
229960000554 metrizamide Drugs 0.000 description 2
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
239000013642 negative control Substances 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
239000002356 single layer Substances 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
238000009331 sowing Methods 0.000 description 2
208000002254 stillbirth Diseases 0.000 description 2
231100000537 stillbirth Toxicity 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
230000009897 systematic effect Effects 0.000 description 2
210000001550 testis Anatomy 0.000 description 2
229940033663 thimerosal Drugs 0.000 description 2
238000004448 titration Methods 0.000 description 2
238000012546 transfer Methods 0.000 description 2
238000012795 verification Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
JMNQYAXOMXHZAP-ZETCQYMHSA-N (2s)-5-(diaminomethylideneamino)-2-(propylamino)pentanoic acid Chemical compound CCCN[C@H](C(O)=O)CCCNC(N)=N JMNQYAXOMXHZAP-ZETCQYMHSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
101150096316 5 gene Proteins 0.000 description 1
208000007407 African swine fever Diseases 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241001292006 Arteriviridae Species 0.000 description 1
206010003591 Ataxia Diseases 0.000 description 1
NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
240000008213 Brosimum alicastrum Species 0.000 description 1
206010006500 Brucellosis Diseases 0.000 description 1
101100137193 Cassava vein mosaic virus ORF 3 gene Proteins 0.000 description 1
101100286205 Cassava vein mosaic virus ORF 4 gene Proteins 0.000 description 1
101100488875 Cassava vein mosaic virus ORF 5 gene Proteins 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010010947 Coordination abnormal Diseases 0.000 description 1
241000711573 Coronaviridae Species 0.000 description 1
XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000710188 Encephalomyocarditis virus Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000186811 Erysipelothrix Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
206010022653 Intestinal haemorrhages Diseases 0.000 description 1
206010024238 Leptospirosis Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
241001430197 Mollicutes Species 0.000 description 1
231100000678 Mycotoxin Toxicity 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
101001114132 Naja sputatrix Neutral phospholipase A2 B Proteins 0.000 description 1
101001114133 Naja sputatrix Neutral phospholipase A2 muscarinic inhibitor Proteins 0.000 description 1
108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
208000007542 Paresis Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
235000014676 Phragmites communis Nutrition 0.000 description 1
108091036407 Polyadenylation Proteins 0.000 description 1
208000005107 Premature Birth Diseases 0.000 description 1
241000220324 Pyrus Species 0.000 description 1
206010037688 Q fever Diseases 0.000 description 1
241001080180 Quinta Species 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
241000555745 Sciuridae Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
101001120268 Streptomyces griseus Protein Y Proteins 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
239000012984 antibiotic solution Substances 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
229960002319 barbital Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000009534 blood test Methods 0.000 description 1
238000009529 body temperature measurement Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
201000000902 chlamydia Diseases 0.000 description 1
208000012538 chlamydia trachomatis infectious disease Diseases 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
235000021316 daily nutritional intake Nutrition 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
210000002409 epiglottis Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000005755 formation reaction Methods 0.000 description 1
229940044627 gamma-interferon Drugs 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
150000003278 haem Chemical class 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
208000016290 incoordination Diseases 0.000 description 1
238000009776 industrial production Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000009533 lab test Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
244000144972 livestock Species 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000008774 maternal effect Effects 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
208000030194 mouth disease Diseases 0.000 description 1
239000002636 mycotoxin Substances 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-M octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000016087 ovulation Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
235000021017 pears Nutrition 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
PYOZTOXFQNWBIS-UHFFFAOYSA-N phenol;sodium Chemical compound [Na].OC1=CC=CC=C1 PYOZTOXFQNWBIS-UHFFFAOYSA-N 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
230000027317 positive regulation of immune response Effects 0.000 description 1
235000005828 ramon Nutrition 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012770 revaccination Methods 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
210000002993 trophoblast Anatomy 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10051—Methods of production or purification of viral material
- C12N2770/10052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

NL9401414A 1993-09-17 1994-08-31 Virusstam en vaccin ter voorkoming van varkensreproductie- en -respiratiesyndroom. NL194940C (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ES9301973		1993-09-17
ES9301973A ES2074950B1 (es)	1993-09-17	1993-09-17	Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.

Publications (3)

Publication Number	Publication Date
NL9401414A NL9401414A (nl)	1995-04-18
NL194940B NL194940B (nl)	2003-04-01
NL194940C true NL194940C (nl)	2003-08-04

Family

ID=8283072

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL9401414A NL194940C (nl)	1993-09-17	1994-08-31	Virusstam en vaccin ter voorkoming van varkensreproductie- en -respiratiesyndroom.

Country Status (7)

Country	Link
DE (1)	DE4432338C2 (it)
DK (1)	DK173128B1 (it)
ES (1)	ES2074950B1 (it)
FR (1)	FR2709966B1 (it)
GB (1)	GB2282811B (it)
IT (1)	IT1267448B1 (it)
NL (1)	NL194940C (it)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2069435T4 (es)	1991-06-06	1997-06-16	Stichting Centr Diergeneeskund	Composicion de vacuna para vacunar animales, en concreto mamiferos y mas concretamente cerdos o cochinos.
US6042830A (en) *	1992-08-05	2000-03-28	Boehringer Ingelheim Vetmedica, Inc.	Viral agent associated with mystery swine disease
US6773908B1 (en)	1992-10-30	2004-08-10	Iowa State University Research Foundation, Inc.	Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US6592873B1 (en)	1992-10-30	2003-07-15	Iowa State University Research Foundation, Inc.	Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
US6380376B1 (en)	1992-10-30	2002-04-30	Iowa State University Research Foundation	Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US5695766A (en)	1992-10-30	1997-12-09	Iowa State University Research Foundation	Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
US6251397B1 (en)	1992-10-30	2001-06-26	Iowa State University Research Foundation, Inc.	Proteins encoded by polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus and immunogenic compositions containing the same
DK53595A (da) *	1994-05-13	1995-11-14	Iberica Cyanamid	Rekombinante PRRSV-proteiner, diagnostiske kits og vaccine indeholdende sådanne rekombinante PRRSV-proteiner
ES2078187B1 (es) *	1994-05-13	1996-07-16	Cynamid Iberica S A	Proteinas recombinantes de prrs, kits de diagnostico y vacunas que contienen dichas proteinas recombinantes.
US5690940A (en) *	1995-06-21	1997-11-25	Regents Of The University Of Minnesota	Low pathogencity PRRS live virus vaccines and methods of preparation thereof
US5866401A (en) *	1996-03-01	1999-02-02	Schering Corporation	Porcine reproductive and respiratory syndrome vaccine
CO4600644A1 (es) *	1996-03-01	1998-05-08	Schering Corp	Vacuna contra el sindrome reproductivo y respiratorio porcino
EP0839912A1 (en)	1996-10-30	1998-05-06	Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo)	Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
SK286063B6 (sk)	1997-05-06	2008-02-05	Boehringer Ingelheim Vetmedica Gmbh	Peptid vyvolávajúci tvorbu protilátok, protilátkareaktívna s týmto peptidom a diagnostická súpravaobsahujúca peptid a protilátku
UA78180C2 (uk)	1997-10-03	2007-03-15	Меріаль	Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
CA2440933A1 (en)	1998-12-22	2000-06-22	Pfizer Products Inc.	An infectious cdna clone of north american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof
EP1157121B1 (en)	1999-03-08	2013-04-24	Boehringer Ingelheim Vetmedica GmbH	Prrsv replicon
JP4778620B2 (ja)	1999-04-22	2011-09-21	ユナイテッドステイツデパートメントオブアグリカルチャー	分離株ｊａ−１４２に基づく、豚繁殖・呼吸障害症候群ワクチン
RU2232596C1 (ru) *	2002-10-16	2004-07-20	Федеральное государственное учреждение Всероссийский научно-исследовательский институт защиты животных	Способ изготовления вирус-вакцины против репродуктивно-респираторного синдрома свиней
EP1781327A4 (en)	2004-06-18	2009-02-25	Univ Minnesota	IDENTIFICATION OF VIRAL INFECTED AND VACCINATED ORGANISMS
US7632636B2 (en)	2004-09-21	2009-12-15	Boehringer Ingelheim Vetmedica, Inc.	Porcine reproductive and respiratory syndrome isolates and methods of use
EP2460819A3 (en)	2004-12-30	2013-01-09	Boehringer Ingelheim Vetmedica, Inc.	PCV2 immunogenic compositions and methods of producing such compositions
PL2369001T3 (pl)	2005-06-24	2017-06-30	Regents Of The University Of Minnesota	Wirusy PRRS, ich klony zakaźne, mutanty i sposoby stosowania
BR122015028489B1 (pt)	2005-12-29	2021-10-13	Boehringer Ingelheim Animal Health Usa Inc	Vacina de combinação multivalente contra pcv2, bem como uso de uma proteína orf2 na preparação da mesma
RU2316346C2 (ru) *	2006-02-20	2008-02-10	Федеральное государственное учреждение "Федеральный центр охраны здоровья животных" (ФГУ "ВНИИЗЖ")	Вакцина против репродуктивно-респираторного синдрома свиней эмульсионная инактивированная
TWI627281B (zh)	2009-09-02	2018-06-21	百靈佳殷格翰家畜藥品公司	降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
DK2558118T3 (da) *	2010-04-16	2019-08-26	Univ Gent	Krydsbeskyttende vaccine mod reproduktions- og respirationssyndromvirus hos svin
UA117272C2 (uk)	2011-02-17	2018-07-10	Бьорінгер Інгельхайм Ветмедіка Гмбх	Новий європейський штам prrsv
CN103370077B (zh)	2011-02-17	2016-10-26	贝林格尔.英格海姆维特梅迪卡有限公司	猪繁殖与呼吸综合征病毒的商业化规模生产方法
WO2013017568A1 (en)	2011-07-29	2013-02-07	Boehringer Ingelheim Vetmedica Gmbh	INFECTIOUS cDNA CLONE OF EUROPEAN PRRS VIRUS AND USES THEREOF
US9187731B2 (en)	2011-07-29	2015-11-17	Boehringer Ingelheim Vetmedica Gmbh	PRRS virus inducing type I interferon in susceptible cells
US9120859B2 (en)	2012-04-04	2015-09-01	Zoetis Services Llc	Mycoplasma hyopneumoniae vaccine
UA114504C2 (uk)	2012-04-04	2017-06-26	Зоетіс Сервісіз Ллс	Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk)	2012-04-04	2017-06-26	Зоетіс Сервісіз Ллс	Комбінована вакцина pcv та mycoplasma hyopneumoniae
CN105073130A (zh)	2013-03-15	2015-11-18	勃林格殷格翰动物保健公司	猪生殖与呼吸综合征病毒、组合物、疫苗及使用方法
MX2020010248A (es)	2013-12-20	2020-10-16	Boehringer Ingelheim Vetmedica Gmbh	Variante del virus prrs, clon de adnc del virus europeo y sus usos.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2069435T4 (es) *	1991-06-06	1997-06-16	Stichting Centr Diergeneeskund	Composicion de vacuna para vacunar animales, en concreto mamiferos y mas concretamente cerdos o cochinos.
HU220113B (hu) *	1991-10-14	2001-11-28	Akzo N.V.	Sertések reproduktív és légzőszervi tünetegyüttese elleni vakcina, eljárás előállítására és alkalmazása
FR2686097B1 (fr) *	1992-01-14	1994-12-30	Rhone Merieux	Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie.
DE69426228T2 (de) *	1993-02-08	2001-03-01	Bayer Ag	Verfahren zum Vermehren des das Reproduktions- und Atemwegs-Syndrom verursachenden Schweinevirus und dessen Verwendung als Impfstoff.

1993
- 1993-09-17 ES ES9301973A patent/ES2074950B1/es not_active Expired - Fee Related
1994
- 1994-08-31 NL NL9401414A patent/NL194940C/nl not_active IP Right Cessation
- 1994-09-06 DK DK199401028A patent/DK173128B1/da not_active IP Right Cessation
- 1994-09-07 FR FR9410722A patent/FR2709966B1/fr not_active Expired - Fee Related
- 1994-09-09 IT IT94TO000713 patent/IT1267448B1/it active IP Right Grant
- 1994-09-10 DE DE19944432338 patent/DE4432338C2/de not_active Expired - Lifetime
- 1994-09-16 GB GB9418775A patent/GB2282811B/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
FR2709966B1 (fr)	1997-05-23
DE4432338A1 (de)	1995-05-04
DE4432338C2 (de)	1997-10-30
GB9418775D0 (en)	1994-11-02
ITTO940713A0 (it)	1994-09-09
DK102894A (da)	1995-03-18
GB2282811A (en)	1995-04-19
ITTO940713A1 (it)	1996-03-09
NL9401414A (nl)	1995-04-18
NL194940B (nl)	2003-04-01
ES2074950A1 (es)	1995-09-16
IT1267448B1 (it)	1997-02-05
DK173128B1 (da)	2000-01-31
FR2709966A1 (fr)	1995-03-24
ES2074950B1 (es)	1996-03-16
GB2282811B (en)	1998-02-18

Publication	Publication Date	Title
NL194940C (nl)	2003-08-04	Virusstam en vaccin ter voorkoming van varkensreproductie- en -respiratiesyndroom.
AU703084B2 (en)	1999-03-18	Low pathogenicity prrs live virus vaccines and methods of preparation thereof
Cook et al.	1999	Preliminary antigenic characterization of an avian pneumovirus isolated from commercial turkeys in Colorado, USA
ES2353952T3 (es)	2011-03-08	Ácidos nucleicos que codifican para vacunas contra el virus del síndrome reproductivo y respiratorio porcino (prrsv).
ES2349041T3 (es)	2010-12-22	Derivados de hidantoina para el tratamiento de trastornos inflamatorios.
US9579373B2 (en)	2017-02-28	Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
KR19990014840A (ko)	1999-02-25	불가사의한 돼지의 질병과 관련된 바이러스성 약제
TW201300538A (zh)	2013-01-01	新穎歐洲型ｐｒｒｓｖ株
WO1998000165A1 (en)	1998-01-08	Porcine reproductive and respiratory syndrome vaccine
US4904468A (en)	1990-02-27	Canine coronavirus vaccine
CN106554944A (zh)	2017-04-05	猪流行性腹泻病毒弱毒株及其制备的疫苗组合物和应用
CN107537031A (zh)	2018-01-05	一种预防猪繁殖与呼吸综合征的疫苗组合物及其制备方法和应用
RU2403063C1 (ru)	2010-11-10	Вакцина инактивированная комбинированная против вирусной диареи, рота-, коронавирусной болезней и эшерихиоза крупного рогатого скота
JP4050312B2 (ja)	2008-02-20	ニワトリ貧血因子ブロイラーワクチン
Yousif et al.	2006	Oral administration of hyperimmune IgY: an immunoecological approach to curbing acute infectious bursal disease virus infection
RU2395299C1 (ru)	2010-07-27	Вакцина инактивированная комбинированная против инфекционного ринотрахеита, вирусной диареи, рота-, коронавирусной болезней и лептоспироза крупного рогатого скота
RU2269361C2 (ru)	2006-02-10	Вакцина ассоциированная эмульсионная инактивированная против репродуктивно-респираторного синдрома и парвовирусной инфекции свиней
RU2395297C1 (ru)	2010-07-27	Вакцина инактивированная комбинированная против инфекционного ринотрахеита, вирусной диареи и лептоспироза крупного рогатого скота
HUP0202389A2 (hu)	2002-12-28	Macskafélék calicivírus-betegsége elleni, inaktivált vakcina
JP7513614B2 (ja)	2024-07-09	プライム－ブーストワクチン接種レジメン
RU2817873C2 (ru)	2024-04-22	Схема вакцинации "прайм-буст"
Garmendia et al.	2021	Porcine Reproductive and Respiratory Syndrome
KR20050040172A (ko)	2005-05-03	돼지 생식기호흡기 증후군 바이러스 불활화 백신의 제조방법
MXPA97010149A (en)	1998-11-09	Live pathogenicity live virus vaccines and methods of preparation of mis
MXPA99005452A (en)	2002-03-26	Recombinant equine herpesvirus type 1 (ehv-1) comprising a dysfunctional gene 71 region and use thereof as a vaccine

Legal Events

Date	Code	Title	Description
1995-04-18	A1A	A request for search or an international-type search has been filed
1996-01-02	BC	A request for examination has been filed
1996-09-02	BB	A search report has been drawn up
1997-01-06	BC	A request for examination has been filed
1997-07-01	BI	The patent application has been withdrawn
2014-09-10	V4	Discontinued because of reaching the maximum lifetime of a patent	Effective date: 20140831